The role of VIP and somatostatin in the control of GH and prolactin release in anorexia nervosa and in obesity.
Baranowska
B
B
Department of Neuroendocrinology, Medical Center of Postgraduate Education, Warsaw, Poland. zncmkp@polbox.com
Radzikowska
M
M
Wasilewska-Dziubinska
E
E
Roguski
K
K
Borowiec
M
M
D000293:Adolescent; D000328:Adult; D000856:Anorexia Nervosa / Q000097:blood / Q000503:physiopathology*; D016022:Case-Control Studies; D003000:Clonidine / Q000008:administration & dosage; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D019382:Human Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D009765:Obesity / Q000097:blood / Q000503:physiopathology*; D011388:Prolactin / Q000378:metabolism*; D013004:Somatostatin / Q000097:blood / Q000502:physiology*; D014660:Vasoactive Intestinal Peptide / Q000097:blood / Q000502:physiology*
D019382:Human Growth Hormone; D007987:Gonadotropin-Releasing Hormone; D014660:Vasoactive Intestinal Peptide; D007980:Levodopa; D013004:Somatostatin; D011388:Prolactin; D003000:Clonidine